Barclays’s Timber Pharmaceuticals, Inc. TMBR Stock Holding History

Barclays’s Portfolio TMBR Stock Details TMBR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-2,072	Closed	-$3.52K	–	5351
2023 Q1	$3.52K	Hold	2,072	–	–	﹤0.01%	4858
2022 Q4	$3.63K	Hold	2,072	–	–	﹤0.01%	5038
2022 Q3	$12K	Hold	2,072	–	–	﹤0.01%	4247
2022 Q2	$33K	Buy	2,072 +1,000	+93%	+$14.6K	﹤0.01%	4212
2022 Q1	$21K	Buy	+1,072	New	+$17.9K	﹤0.01%	4432
2020 Q2	–	Sell	-203	Closed	-$37K	–	6438
2020 Q1	$37K	Hold	203	–	–	﹤0.01%	5396
2019 Q4	$52K	Sell	203 -89	-30%	-$17.3K	﹤0.01%	5729
2019 Q3	$58K	Buy	+292	New	+$70K	﹤0.01%	5842
2018 Q4	–	Sell	-40	Closed	-$115K	–	7507
2018 Q3	$115K	Sell	40 -14	-26%	-$40.5K	﹤0.01%	5431
2018 Q2	$181K	Buy	54 +30	+125%	+$101K	﹤0.01%	4810
2018 Q1	$84K	Buy	+24	New	+$71.2K	﹤0.01%	5513
2016 Q4	–	Hold	0	–	–	–	6918
2016 Q3	–	Hold	0	–	–	–	6872

Other funds holding TMBR

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

CPG

Cornerstone Planning Group Fairfield, New Jersey $749M AUM 17.97% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

SPIA

Steward Partners Investment Advisory New York $19.6B AUM 22.89% 1-Year Est. Return

Barclays's TMBR Position: Q2 2023 in Review

Barclays sold out of Timber Pharmaceuticals, Inc. (TMBR) in Q2 2023, closing a stake of 2,072 shares — an estimated $3.52K sold.

Barclays first reported a position in TMBR in Q1 2018 and held it in 11 quarters. The position peaked at $181K in Q2 2018. 9 funds tracked by Wall St. Rank hold TMBR as of Q2 2023.

Barclays reported no remaining Timber Pharmaceuticals, Inc. position as of Q2 2023 after selling out during the quarter.
Barclays sold 2,072 Timber Pharmaceuticals, Inc. shares in Q2 2023, an estimated $3.52K.
Barclays first reported a position in Timber Pharmaceuticals, Inc. in Q1 2018 and held it in 11 quarters.
Barclays's Timber Pharmaceuticals, Inc. position peaked at $181K in Q2 2018.
9 funds tracked by Wall St. Rank held Timber Pharmaceuticals, Inc. as of Q2 2023.

Based on Barclays's 13F filing for Q2 2023, filed 3 Aug 2023.